Sign In
Buy CRNX
$83.67
+0.0900 (+0.108%)
At Close: Jul 13, 2026
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
02:27pm, Monday, 13'th Jul 2026
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
05:03pm, Saturday, 11'th Jul 2026
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strat
Why This Pharmaceutical Stock Jumped Close to 100% This Week
03:02pm, Friday, 10'th Jul 2026
It is getting acquired by a larger firm in the sector.
Why Crinetics Stock Soared 99% This Week
01:29pm, Thursday, 09'th Jul 2026
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
01:22pm, Thursday, 09'th Jul 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of C
Vertex's Crinetics Deal Balances Growth with Integration Risk
09:05am, Wednesday, 08'th Jul 2026
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of dir
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
03:55am, Wednesday, 08'th Jul 2026
CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
03:28am, Wednesday, 08'th Jul 2026
Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing.
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
11:00pm, Tuesday, 07'th Jul 2026
Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a late-stage candidate with more than $5 billion in comb
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transaction may contain terms that could limit superior competing offers.
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
10:31am, Tuesday, 07'th Jul 2026
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.
Crinetics shares surge after Vertex agrees to $10B cash buyout
09:38am, Tuesday, 07'th Jul 2026
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Crinetics Pharmaceuticals, Inc. (CRNX)
09:28am, Tuesday, 07'th Jul 2026
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - July 7, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Crinetics Pharmaceutica
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
08:24am, Tuesday, 07'th Jul 2026
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion
